COMPOSITIONS AND METHODS FOR TREATING EYE DISORDERS AND CONDITIONS

• US 20080153909A1
• Filed: 10/17/2007
• Published: 06/26/2008
• Est. Priority Date: 07/01/2004
• Status: Abandoned Application

• Current Assignee: Johnson & Johnson Vision Care Incorporated (Johnson & Johnson), The Schepens Eye Research Institute Inc (Mass General Brigham, Inc.)
• Original Assignee: Johnson & Johnson Vision Care Incorporated (Johnson & Johnson), The Schepens Eye Research Institute Inc (Mass General Brigham, Inc.)
• Inventors: Copper, Lenora, Schaumberg, Debra, Mahadevan, Shiv, Lorenz, Kathy Osborn, DANA, REZA, Rashid, Saadia, Molock, Frank
• Application Number:
  US11/873,478
• Publication Number:
  US 20080153909A1
• Time in Patent Office: Days
• US Class Current: 514/560
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/202 having three or more double bonds, e.g. linolenic eicosanoids, e.g. leukotrienes A61K31/557
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/107 Emulsions ; Emulsion preconcentrates; Micelles composition of emulsions A61K47/00
• CPC Class Codes: A61P 27/00 Drugs for disorders of the senses
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/04 Artificial tears; Irrigation solutions
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14

Abstract

The present invention relates to compositions comprising omega-6 and/or omega-3 fatty acids and uses thereof. The present invention also relates to methods of treatment using such compositions.

Claims

1. An ophthalmic composition comprising at least one omega-6 fatty acid and at least one omega-3 fatty acid.

2. The composition of claim 1, wherein said omega-6 fatty acid is non inflammation promoting.

3. The composition of claim 1, wherein said composition is substantially free of linoleic acid and/or arachidonic acid.

4. The composition of claim 1, wherein said composition comprises eye drops.

5. The composition of claim 1, wherein said omega-3 fatty acid compound is alpha linolenic acid or a derivative thereof.

6. The composition of claim 1 wherein said omega-6 fatty acid compound is gammalinolenic acid, dihomogammalinolenic acid, or both.

7. The composition of claim 1, wherein said omega-3 fatty acid compound is eicosapentaenoic acid, docosahexaenoic acid, or both.

8. The composition of claim 1, wherein said composition is formulated for topical administration.

9. The composition of claim 1, wherein said composition is an injectable composition.

10. The composition of claim 1, wherein said composition comprises a sustained release device.

11. The composition of claim 1, wherein ratio of said omega 3 fatty acid to omega 6 fatty acid is about 10:

1 to about 1;

1.

12. The composition of claim 1, wherein ratio of said omega 3 fatty acid to omega 6 fatty acid is about 5:

1 to about 1;

1.

13. The composition of claim 1, wherein ratio of said omega 3 fatty acid to omega 6 fatty acid is about 5:

1.

19. A method for normalizing the ratio of omega 3 fatty acids to omega 6 fatty acids in an eye of an individual comprising administering the composition of claim 1.

14. A sterile preparation for administration to the eye comprising at least one omega-6 fatty acid and at least one omega-3 fatty acid.

15. The sterile preparation of claim 14, wherein said preparation is substantially free of linoleic acid and/or arachidonic acid.

16. The sterile preparation of claim 14 wherein said omega-3 fatty acid comprises eicosapentaenoic acid, docosahexaenoic acid, or both.

17. The sterile preparation of claim 15 wherein said omega-6 fatty acid comprises gammalinolenic acid, dihomogammalinolenic acid, or both.

18. The sterile preparation of claim 14 wherein said administration is topical administration.

20. A method of preparing a composition comprising an omega-6 and/or omega-3 fatty acid comprising

a) mixing a first surfactant with a saline solution;

b) contacting at least one omega-6 acid and/or at least one omega-3 fatty acid with the solution of step a).

21. The method of claim 20, wherein said at least omega-6 fatty acid and/or at least one omega-3 fatty acid is contacted with a solution of step a) over an hour.

22. An ophthalmic composition comprising at least one omega-3 fatty acid wherein the concentration of said fatty acid is in the range from about 0.1 weight % to about 0.4 weight %.

23. The ophthalmic composition of claim 22, wherein the concentration of said fatty acid is 0.1 weight %.

24. The ophthalmic composition of claim 22, wherein the concentration of said fatty acid is 0.4 weight %.

25. The composition of claim 22 wherein the omega-3 fatty acid is alpha-linoleic acid or a derivative thereof.

26. The composition of claim 22 wherein the omega-3 fatty acid is eicosapentaenoic acid, docosahexaenoic acid or a combination thereof.

27. A method of treating dry eye in an individual comprising contacting an ocular surface of said individual with a composition comprising a therapeutically effective amount of an omega-3 fatty acid.

28. The method of claim 27 wherein the concentration of omega-3 fatty acid is from about 0.01 weight % to about 10 weight %.

29. The method of claim 27 wherein said omega-3 fatty acid is alpha-linoleic acid, eicosapentaenoic acid, docosahexaenoic acid, or a combination thereof.

30. A method of treating adnexal inflammation comprising administering to an affected eye of an individual a composition comprising a therapeutically effective amount of an omega-3 fatty acid.

31. The method of claim 30, wherein said individual has been identified as in need thereof.

32. The method of claim 30, wherein said omega-3 fatty acid is eicosapentenoic acid, docosahexaenoic acid, alpha-linoleic acid or a combination thereof.

33. A sterile preparation for administration to the eye comprising at least one omega-3 fatty acid wherein the fatty acid is at a concentration of from about 0.1 weight % to about 0.4 weight %.

34. The sterile preparation of claim 33 wherein said omega-3 fatty acid is eicosapentenoic acid, docosahexaenoic acid, alpha-linoleic acid or a combination thereof.

35. An ophthalmic composition comprising at least one omega-6 fatty acid wherein the concentration of said fatty acid is in the range from about 0.1 weight % to about 0.4 weight %.

36. The ophthalmic composition of claim 35, wherein the concentration of said fatty acid is 0.1 weight %.

37. The ophthalmic composition of claim 35, wherein the concentration of said fatty acid is 0.4 weight %.

38. The composition of claim 35 wherein the omega-6 fatty acid is gammalinolenic acid or dihomogammalinolenic acid.

39. A method of treating dry eye in an individual comprising contacting an ocular surface of said individual with a composition comprising a therapeutically effective amount of an omega-6 fatty acid.

40. The method of claim 39 wherein the concentration of omega-6 fatty acid is from about 0.01 weight % to about 5 weight %.

41. The method of claim 40 wherein said omega-6 fatty acid is gammalinolenic acid or dihomogammalinolenic acid, or a combination thereof.

42. A method of treating adnexal inflammation comprising administering to an affected eye of an individual a composition comprising a therapeutically effective amount of an omega-6 fatty acid.

43. The method of claim 42, wherein said individual has been identified as in need thereof.

44. The method of claim 42, wherein said omega-6 fatty acid is gammalinolenic acid or dihomogammalinolenic acid or a combination thereof.

45. A sterile preparation for administration to the eye comprising at least one omega-6 fatty acid wherein the fatty acid is at a concentration of from about 0.1 weight % to about 0.4 weight %.

46. The sterile preparation of claim 45 wherein said omega-3 fatty acid is gammalinolenic acid or dihomogammalinolenic acid or a combination thereof.